Microencapsulated mammalian cells for simultaneous production of VEGF165b and IFNα

Download
  1. Get@NRC: Microencapsulated mammalian cells for simultaneous production of VEGF165b and IFNα (Opens in a new window)
DOIResolve DOI: http://doi.org/10.3109/10731199.2011.560120
AuthorSearch for: ; Search for: ; Search for:
TypeArticle
Journal titleArtificial Cells, Nanomedicine, and Biotechnology
Volume40
Issue1-2
Pages16; # of pages: 6
Subjectartificial cell; microcapsule; co-encapsulation; angiogenesis; IFNα; VEGF165b; alginate; poly-L-lysine; cell therapy
AbstractTargeted and simultaneous delivery VEGF165b and IFN alpha in anti-angiogenic and other applications could offer several advantages. For this a system was design using artificial cell alginate-poly-L-lysine- alginate (APA) microcapsules. Result confirms the ability of this system for simultaneous production of these proteins for 28-days. The IFN alpha on a 3 days period increased from 8 ± 0.36 μg/ml at day 10 to 27 ± 2.4 μg/ml at day 16 and then dropped to 6.5 ± 0.5 μg/ml. The VEGF165b on a 3 days period increased from 2.7 ± 0.7 μg/ml at day 10 to 6.9 ± 1 μg/ml at day 16.
Publication date
PublisherInforma Healthcare
LanguageEnglish
AffiliationNRC Biotechnology Research Institute; National Research Council Canada
Peer reviewedYes
NRC number53203
NPARC number21268296
Export citationExport as RIS
Report a correctionReport a correction
Record identifier77acc44e-2dce-4e5e-a1a9-7df93a98f5a1
Record created2013-06-17
Record modified2016-05-09
Bookmark and share
  • Share this page with Facebook (Opens in a new window)
  • Share this page with Twitter (Opens in a new window)
  • Share this page with Google+ (Opens in a new window)
  • Share this page with Delicious (Opens in a new window)